Close Menu

NEW YORK – Oxgene and the Native Antigen Company announced Thursday they have agreed to partner to increase antigen manufacturing capabilities reagents for the development of SARS-CoV-2 diagnostics and vaccines.

The companies will use Oxgene's Adenoviral Protein Machine technology to deliver high-purity recombinant proteins. The technology uses an adenoviral expression vector and allows for scalable production of viral proteins in mammalian cells by tricking the adenovirus into making SARS-CoV-2 proteins. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.